Skip to main content
. 2021 Apr 9;14(4):348. doi: 10.3390/ph14040348

Figure 6.

Figure 6

Biosimilar penetration in Spain over time (adapted from [29]). Biosimilar uptake (%) is calculated as volume of biosimilars over volume of biosimilars plus the originator product (DDDs). * Chondroitin sulfate and the three biosimilars marketed before 2009 (somatropin, filgrastim and epoetin) were excluded to avoid distorting the mean. SOM: somatropin; FIL: filgrastim; EPO: epoetin; FOL: follitropin alfa; INF: infliximab; INS: insuline glargine; ETA: etanercept; CHO: chondroitin sulfate; RIT: rituximab; TRA: trastuzumab; ENO: sodium enoxaparin; ADA: adalimumab; PEG: pegfilgrastim.